{"id":59160,"date":"2026-03-10T14:14:54","date_gmt":"2026-03-10T06:14:54","guid":{"rendered":"https:\/\/flcube.com\/?p=59160"},"modified":"2026-03-10T14:14:55","modified_gmt":"2026-03-10T06:14:55","slug":"novo-nordisk-settles-with-hims-hers-ozempic-wegovy-distribution-deal-ends-patent-litigation-eliminates-compounded-glp-1-advertising","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59160","title":{"rendered":"Novo Nordisk Settles with Hims &amp; Hers \u2013 Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising"},"content":{"rendered":"\n<p><strong>Novo Nordisk A\/S<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) announced a <strong>settlement agreement<\/strong> with <strong>telehealth company Hims &amp; Hers<\/strong> effective <strong>later this month<\/strong>, securing <strong>branded Ozempic and Wegovy distribution<\/strong> through the platform at <strong>affordable self-pay prices<\/strong> while <strong>ending Hims &amp; Hers&#8217; compounded GLP-1 advertising and offerings<\/strong>. Under terms, Hims &amp; Hers will <strong>shift its business model<\/strong> to focus on <strong>FDA-approved semaglutide medicines<\/strong>, transition existing patients to branded alternatives, and <strong>cease marketing of compounded products<\/strong>. Novo Nordisk is <strong>dismissing its patent infringement lawsuit<\/strong> against Hims &amp; Hers while <strong>reserving refiling rights<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-agreement-structure\">Agreement Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Novo Nordisk (plaintiff\/settlor) + Hims &amp; Hers (defendant\/licensee)<\/td><\/tr><tr><td><strong>Effective Date<\/strong><\/td><td>Late March 2026<\/td><\/tr><tr><td><strong>Novo Nordisk Products<\/strong><\/td><td>Ozempic (semaglutide injection: 0.5\u202fmg, 1\u202fmg, 2\u202fmg); Wegovy (semaglutide tablets: 1.5\u202fmg, 4\u202fmg, 9\u202fmg, 25\u202fmg; injection: 0.25\u202fmg, 0.5\u202fmg, 1\u202fmg, 1.7\u202fmg, 2.4\u202fmg)<\/td><\/tr><tr><td><strong>Pricing<\/strong><\/td><td>&#8220;Affordable self-pay prices&#8221; \u2013 parity with other telehealth platforms<\/td><\/tr><tr><td><strong>Hims &amp; Hers Commitment<\/strong><\/td><td>\u2022 Cease compounded GLP-1 advertising\/marketing<br>\u2022 Remove compounded offerings from platform<br>\u2022 Transition existing patients to FDA-approved alternatives<br>\u2022 Focus business model on branded medicines<\/td><\/tr><tr><td><strong>Legal Resolution<\/strong><\/td><td>Patent infringement lawsuit dismissed; refiling rights reserved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p><strong>Novo Nordisk Objectives:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patent Protection:<\/strong> Enforces intellectual property against compounding pharmacies and telehealth intermediaries<\/li>\n\n\n\n<li><strong>Brand Integrity:<\/strong> Ensures patients receive authentic, quality-controlled semaglutide vs. unregulated compounded alternatives<\/li>\n\n\n\n<li><strong>Market Expansion:<\/strong> Telehealth channel captures price-sensitive, cash-pay patients outside traditional pharmacy benefit structures<\/li>\n\n\n\n<li><strong>Litigation Efficiency:<\/strong> Settlement preferable to protracted court battle with uncertain injunctive relief<\/li>\n<\/ul>\n\n\n\n<p><strong>Hims &amp; Hers Strategic Pivot:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Risk Mitigation:<\/strong> Compounded GLP-1s face FDA enforcement actions and state pharmacy board scrutiny<\/li>\n\n\n\n<li><strong>Revenue Sustainability:<\/strong> Branded product margins lower but legally defensible; volume growth via Novo supply security<\/li>\n\n\n\n<li><strong>Patient Safety:<\/strong> Transition to FDA-approved products reduces liability exposure from compounded drug adverse events<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-dynamics\">Market Context &amp; Competitive Dynamics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Compounded GLP-1 Market<\/strong><\/td><td>Estimated $2-3 billion U.S. market; FDA and state actions intensifying; settlements may cascade<\/td><\/tr><tr><td><strong>Telehealth Channel<\/strong><\/td><td>Hims &amp; Hers, Ro, Noom competing for GLP-1 access; Novo selective partnership strategy<\/td><\/tr><tr><td><strong>Pricing Pressure<\/strong><\/td><td>&#8220;Affordable self-pay&#8221; language suggests Novo absorbing margin compression to maintain volume vs. Lilly<\/td><\/tr><tr><td><strong>Patent Enforcement<\/strong><\/td><td>Settlement template for remaining litigation (Ro, other platforms); Novo building legal precedent<\/td><\/tr><tr><td><strong>Eli Lilly Response<\/strong><\/td><td>Mounjaro\/Zepbound telehealth strategy may follow; compounded tirzepatide litigation anticipated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-legal-amp-financial-impact\">Legal &amp; Financial Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Patent Litigation<\/strong><\/td><td>Dismissed without prejudice; Novo retains refiling rights if Hims &amp; Hers breaches agreement<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Undisclosed; likely include supply guarantees, minimum volume commitments, marketing co-investment<\/td><\/tr><tr><td><strong>Revenue Impact<\/strong><\/td><td>Incremental U.S. volume through telehealth channel; margin dilution offset by volume growth<\/td><\/tr><tr><td><strong>Investor Sentiment<\/strong><\/td><td>NVO shares benefit from IP enforcement validation and supply chain control<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-implications\">Forward-Looking Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Industry Precedent:<\/strong> Template for Novo settlements with Ro, LifeMD, and other telehealth platforms<\/li>\n\n\n\n<li><strong>Compounding Crackdown:<\/strong> FDA enforcement actions against 503A\/503B pharmacies likely to accelerate post-settlement<\/li>\n\n\n\n<li><strong>Patient Transition:<\/strong> 6-12 month window for Hims &amp; Hers to migrate compounded patients to branded semaglutide<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Similar telehealth partnership models may emerge in EU, UK, and other markets facing compounded drug competition<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding settlement enforcement, telehealth channel growth, and competitive dynamics in the GLP-1 market. Actual results may differ due to patient transition rates, remaining litigation outcomes, and regulatory actions against compounding pharmacies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk A\/S (NYSE: NVO) announced a settlement agreement with telehealth company Hims &amp; Hers&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59163,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[39,4361,148,860,86],"class_list":["post-59160","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-diabetes","tag-hot-targets","tag-novo-nordisk","tag-nyse-nvo","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk Settles with Hims &amp; Hers \u2013 Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced a settlement agreement with telehealth company Hims &amp; Hers effective later this month, securing branded Ozempic and Wegovy distribution through the platform at affordable self-pay prices while ending Hims &amp; Hers&#039; compounded GLP-1 advertising and offerings. Under terms, Hims &amp; Hers will shift its business model to focus on FDA-approved semaglutide medicines, transition existing patients to branded alternatives, and cease marketing of compounded products. Novo Nordisk is dismissing its patent infringement lawsuit against Hims &amp; Hers while reserving refiling rights.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59160\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Settles with Hims &amp; Hers \u2013 Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced a settlement agreement with telehealth company Hims &amp; Hers effective later this month, securing branded Ozempic and Wegovy distribution through the platform at affordable self-pay prices while ending Hims &amp; Hers&#039; compounded GLP-1 advertising and offerings. Under terms, Hims &amp; Hers will shift its business model to focus on FDA-approved semaglutide medicines, transition existing patients to branded alternatives, and cease marketing of compounded products. Novo Nordisk is dismissing its patent infringement lawsuit against Hims &amp; Hers while reserving refiling rights.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59160\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-10T06:14:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-10T06:14:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1003.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59160#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59160\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Settles with Hims &amp; Hers \u2013 Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising\",\"datePublished\":\"2026-03-10T06:14:54+00:00\",\"dateModified\":\"2026-03-10T06:14:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59160\"},\"wordCount\":539,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59160#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1003.webp\",\"keywords\":[\"Diabetes\",\"Hot targets\",\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59160#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59160\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59160\",\"name\":\"Novo Nordisk Settles with Hims &amp; Hers \u2013 Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59160#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59160#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1003.webp\",\"datePublished\":\"2026-03-10T06:14:54+00:00\",\"dateModified\":\"2026-03-10T06:14:55+00:00\",\"description\":\"Novo Nordisk A\\\/S (NYSE: NVO) announced a settlement agreement with telehealth company Hims & Hers effective later this month, securing branded Ozempic and Wegovy distribution through the platform at affordable self-pay prices while ending Hims & Hers' compounded GLP-1 advertising and offerings. Under terms, Hims & Hers will shift its business model to focus on FDA-approved semaglutide medicines, transition existing patients to branded alternatives, and cease marketing of compounded products. Novo Nordisk is dismissing its patent infringement lawsuit against Hims & Hers while reserving refiling rights.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59160#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59160\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59160#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1003.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1003.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk Settles with Hims & Hers \u2013 Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59160#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Settles with Hims &amp; Hers \u2013 Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Settles with Hims &amp; Hers \u2013 Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk A\/S (NYSE: NVO) announced a settlement agreement with telehealth company Hims & Hers effective later this month, securing branded Ozempic and Wegovy distribution through the platform at affordable self-pay prices while ending Hims & Hers' compounded GLP-1 advertising and offerings. Under terms, Hims & Hers will shift its business model to focus on FDA-approved semaglutide medicines, transition existing patients to branded alternatives, and cease marketing of compounded products. Novo Nordisk is dismissing its patent infringement lawsuit against Hims & Hers while reserving refiling rights.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59160","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Settles with Hims &amp; Hers \u2013 Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising","og_description":"Novo Nordisk A\/S (NYSE: NVO) announced a settlement agreement with telehealth company Hims & Hers effective later this month, securing branded Ozempic and Wegovy distribution through the platform at affordable self-pay prices while ending Hims & Hers' compounded GLP-1 advertising and offerings. Under terms, Hims & Hers will shift its business model to focus on FDA-approved semaglutide medicines, transition existing patients to branded alternatives, and cease marketing of compounded products. Novo Nordisk is dismissing its patent infringement lawsuit against Hims & Hers while reserving refiling rights.","og_url":"https:\/\/flcube.com\/?p=59160","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-10T06:14:54+00:00","article_modified_time":"2026-03-10T06:14:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1003.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59160#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59160"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Settles with Hims &amp; Hers \u2013 Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising","datePublished":"2026-03-10T06:14:54+00:00","dateModified":"2026-03-10T06:14:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59160"},"wordCount":539,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59160#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1003.webp","keywords":["Diabetes","Hot targets","Novo Nordisk","NYSE: NVO","Obesity"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59160#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59160","url":"https:\/\/flcube.com\/?p=59160","name":"Novo Nordisk Settles with Hims &amp; Hers \u2013 Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59160#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59160#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1003.webp","datePublished":"2026-03-10T06:14:54+00:00","dateModified":"2026-03-10T06:14:55+00:00","description":"Novo Nordisk A\/S (NYSE: NVO) announced a settlement agreement with telehealth company Hims & Hers effective later this month, securing branded Ozempic and Wegovy distribution through the platform at affordable self-pay prices while ending Hims & Hers' compounded GLP-1 advertising and offerings. Under terms, Hims & Hers will shift its business model to focus on FDA-approved semaglutide medicines, transition existing patients to branded alternatives, and cease marketing of compounded products. Novo Nordisk is dismissing its patent infringement lawsuit against Hims & Hers while reserving refiling rights.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59160#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59160"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59160#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1003.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1003.webp","width":1080,"height":608,"caption":"Novo Nordisk Settles with Hims & Hers \u2013 Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59160#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Settles with Hims &amp; Hers \u2013 Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1003.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59160"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59160\/revisions"}],"predecessor-version":[{"id":59164,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59160\/revisions\/59164"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59163"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}